<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881138</url>
  </required_header>
  <id_info>
    <org_study_id>C001 CANCER</org_study_id>
    <nct_id>NCT02881138</nct_id>
  </id_info>
  <brief_title>A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for&#xD;
      Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximal tolerance dose (MTD) of RC48-ADC</measure>
    <time_frame>DLT will be evaluated on 28 days of observation period</time_frame>
    <description>Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs</measure>
    <time_frame>Estimated 2 years</time_frame>
    <description>The drug safety was assessed by investigator(s) according to NCI-CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Estimated 2 years</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Estimated 2 years</time_frame>
    <description>Area Under Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Estimated 2 years</time_frame>
    <description>Time for Cmax</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>RC48-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC</intervention_name>
    <arm_group_label>RC48-ADC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form;&#xD;
&#xD;
          -  Aged 18-65 years;&#xD;
&#xD;
          -  ECOG physical condition is 0 or 1;&#xD;
&#xD;
          -  Life expectancy greater than 12 weeks;&#xD;
&#xD;
          -  Diagnosed with histologically or cytologically-confirmed, standard treatment is&#xD;
             ineffective (disease progresses after treatment) or HER2-positive, locally advanced or&#xD;
             metastatic malignant solid tumor patients who cannot tolerate standard therapy, cannot&#xD;
             receive or do not have standard therapy;&#xD;
&#xD;
          -  Human epidermal growth factor receptor 2 (HER2)-positive as measured either by&#xD;
             immunohistochemistry (IHC 2+ and by fluorescence in situ hybridization (FISH) or by&#xD;
             immunohistochemistry (3+);&#xD;
&#xD;
          -  Patients with measurable and appreciable tumor lesions according to Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST 1.1);&#xD;
&#xD;
          -  Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  absolute neutrophil count(ANC) &gt;= 1.5 x 10(9)/L;&#xD;
&#xD;
               -  platelets&gt;=100*10(9)/L;&#xD;
&#xD;
               -  Total serum bilirubin &lt;=1.5*ULN;&#xD;
&#xD;
               -  serum aspartate transaminase (AST) and serum alanine transaminase (ALT)&#xD;
                  &lt;=2.5*upper limit of normal (ULN), or AST and ALT&lt;=5*ULN with hepatic metastasis;&#xD;
&#xD;
               -  Serum creatinine clearance rate &gt;=45ml/min;&#xD;
&#xD;
               -  international normalized ratio (INR) and activated partial thromboplastin time&#xD;
                  (APTT) must be less than or equal to 1.5 times the upper limit of the normal&#xD;
                  range (ULN);&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (e.g. condoms, implants, injectables, combined oral contraceptives, some intrauterine&#xD;
             devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study&#xD;
             entry and during the period of therapy and for 30 days after the last dose of study&#xD;
             drug;&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 50%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy or lactation;&#xD;
&#xD;
          -  Received anti-tumor treatment 4 weeks before study administration, including&#xD;
             chemotherapy, radiotherapy, hormone therapy, biological therapy or immunotherapy,&#xD;
             except the following: Gonadotropin-releasing hormone (GnRH) antagonistic therapy for&#xD;
             prostate cancer and Hormone replacement therapy;&#xD;
&#xD;
          -  Major surgery within 4 weeks of first dose of study drug and not fully recovered;&#xD;
&#xD;
          -  Receiving palliative radiation therapy for bone metastases if administered &lt;= 2 weeks&#xD;
             prior to first study treatment;&#xD;
&#xD;
          -  Toxicity of previous anti-tumor treatment has not recovered to CTCAE [version 4.0] 0-1&#xD;
             (with exception of alopecia);&#xD;
&#xD;
          -  Participated in other clinical drug studies within 4 weeks;&#xD;
&#xD;
          -  Hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or&#xD;
             similar drugs;&#xD;
&#xD;
          -  According to the judgment of the investigator, a clinically significant active&#xD;
             infection;&#xD;
&#xD;
          -  A history of immunodeficiency, including a positive HIV test, or other acquired,&#xD;
             congenital immunodeficiency diseases, or a history of organ transplantation;&#xD;
&#xD;
          -  Uncontrollable systemic diseases including diabetes, hypertension, lung Fibrosis,&#xD;
             acute lung disease, interstitial lung disease, etc.;&#xD;
&#xD;
          -  Congestive heart failure with grade 2 or higher (including grade 2) by the New York&#xD;
             Institute of Cardiology (NYHA) of the United States in the history of diseases such as&#xD;
             acute myocardial infarction, unstable angina, stroke, or transient ischemic attack&#xD;
             within 6 months before enrollment;&#xD;
&#xD;
          -  Insufficient adherence to participate in this clinical study;&#xD;
&#xD;
          -  Treated with Herceptin (Trastuzumab) within 60 days before the trial;&#xD;
&#xD;
          -  Have received systemic steroid therapy for a long time ( short-term users who&#xD;
             discontinue medication&gt; 2 weeks can be selected);&#xD;
&#xD;
          -  Uncontrolled primary or metastatic tumor of brain;&#xD;
&#xD;
          -  Peripheral neuropathy with grade&gt;= 2;&#xD;
&#xD;
          -  People with a history of mental illness that is difficult to control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

